Early Onset Alzheimer's Disease Genomic Study

Alzheimer Disease Clinical Trial

— TGen  

Official title:

Early Onset Alzheimer's Disease Genomic Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03645993
• Other study ID #: 017-176
• Status: Recruiting
• Start date: June 16, 2017
• Est. completion date: June 16, 2022

Study information

• Verified date: October 2019
• Source: Baylor Research Institute
• Contact: Sarah B Burris, MHA
• Phone: 214-818-0382
• Email: Sarah.Burris[@]BSWHealth.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to collect samples from patients with Early-Onset Alzheimer's disease (AD) and their immediate family members for molecular analysis. Samples will be studied in order to understand how molecular changes in the body are related to the development of the disease. Researchers will study your DNA and RNA in order to help doctors diagnose, treat, and monitor people at risk of developing Early-Onset AD in the future.

Description:

About 50 people will be asked to take part in this study at this location. This will include participants with early-onset AD and their parents and siblings. Participants will be asked to: Sign this consent form or have a Legally Authorized Representative sign and provide the participant' health history. The study staff will review the participant's medical history and test results to see if the participant can be part of this study, The study staff will need to know any over-the-counter or prescription drugs, vitamins, or herbs taken by the participant. The study staff will discuss what is required to be part of this study. Participants cannot take part in this study if they have: Family history of early or late-onset Alzheimer's disease, Uncontrolled concurrent illness including psychiatric illness or situations that would limit compliance with the study requirements or the ability to willingly give written or verbal consent. If the participant agrees to take part in this study, one 8mL blood sample (about 2 teaspoons) will be collected from them. If the participant is receiving a clinically indicated blood draw, the blood collections for this study will occur at the same time. Participants may be required to have a research-specific blood draw if they are not scheduled for a blood draw during a regularly scheduled visit.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2
• Est. completion date: June 16, 2022
• Est. primary completion date: June 16, 2022
• Gender: All
• Age group: 40 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis of early-onset Alzheimer's disease based on the NIA-AA diagnostic criteria as determined by the clinician. (Those patients with severe dementia due to Alzheimer's disease or who have impaired decisional capacity, may participate only if their legally authorized representative gives their consent.)

• Male and female patients =40 and =65 years of age.

• Parents and siblings of the participant with Alzheimer's disease.

Exclusion Criteria:

• Family history of early or late-onset Alzheimer's disease.

• Uncontrolled concurrent illness including psychiatric illness or situations that would limit compliance with the study requirements or the ability to willingly give written or verbal informed consent

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Genetic:
• Genetic Testing
A one time blood sample will be taken.

Locations

Country	Name	City	State
United States	Baylor Scott & White AT&T Memory Center	Dallas	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Baylor Research Institute	Translational Genomics Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Biomarkers found in blood	Blood will be taken so that tests can be run to locate a biomarker that will help to diagnose and treat early-onset Alzheimer's disease.	2 years